Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksREDX.L Share News (REDX)

  • There is currently no data for REDX

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET OPEN: Stocks Start Mostly Lower Amid Profit Taking

Tue, 31st Dec 2019 08:51

(Alliance News) - London stocks were lower on Tuesday morning, with some traders remaining away from their desks ahead of the New Year's Day holiday, while others were cashing out of a flagging Santa Rally.

The FTSE 100 index was down 43.63 points, or 0.6%, at 7,543.42 early Tuesday. The mid-cap FTSE 250 index was 33.44 points lower, or 0.2%, at 21,902.82, and the AIM All-Share index was flat at 958.11.

The retreat follows a strong Christmas week for London shares, with the FTSE 250 index of mid-caps reaching a record closing high, breaching the 22,000 mark for the first time.

The Cboe UK 100 index was down 0.6% at 12,783.36. The Cboe 250 was 0.2% lower at 19,815.78, and the Cboe Small Companies flat at 12,247.11.

The London Stock Exchange will close early at 1230 GMT for New Year's Eve. It will re-open on Thursday for a full session.

Sterling was quoted at USD1.3130 early Tuesday, flat with USD1.3136 at the London equities close on Monday.

In other currencies, the euro was trading at USD1.1205 early Tuesday, soft on USD1.1216 late Monday. Against the yen, the dollar was at JPY108.63, down slightly from JPY108.83.

In mainland Europe, the CAC 40 in Paris was down 0.4%. Financial markets in France will close early on Tuesday, while German markets are completely closed for New Year's Eve. Italy and Switzerland also are closed all day.

In Asia on Tuesday, financial markets were closed in Japan. In China, the Shanghai Composite ended up 0.3%, while the Hang Seng index in Hong Kong closed down 0.5%.

Tokyo will remain shut until Monday, while the Shanghai and Hong Kong markets are closed on New Year's Day but reopen on Thursday.

Back in London, HSBC Holdings started the day 0.6% lower after the Financial Times reported that the bank is planning to expand its exchange traded fund range in 2020 in order to revitalise its underperforming asset management business.

Nicholas Moreau, who was appointed chief executive of HSBC's asset management division in August, has devised a series of initiatives aimed at reinvigorating growth at a time when the London-listed bank is aggressively cutting costs, the FT said.

In the first half of 2020, HSBC will launch eight ETF's employing environmental, social and governance metrics to tap into rising investor demand for ESG-focused strategies.

HSBC also plans to develop a fixed income ETF platform in 2020 and to launch a range of precious metals tracker funds later in the year, the FT noted.

On AIM, Redx Pharma surged 31% in early trade to 8.68 pence. The company reported it is in "active" discussions with Samuel Waksal and associates, which could lead to a possible cash offer for the company.

In the meantime, the drug discovery and development company called on its shareholders to vote in favour of the conversion of a GBP2.5 million loan into shares. A general meeting will be held on January 21.

"We believe that this short-term funding solution will allow us time to secure the necessary longer-term funding that will enable us to advance our innovative pipeline of novel precision medicines for cancer and fibrosis," explained Chair Iain Ross.

The loan agreement was signed back in June with Moulton Goodies Ltd, Redx's largest shareholder which has over 18% stake, for a fixed rate secured loan note facility of up to GBP2.5 million. The loan is repayable in full on Tuesday. However, Moulton has requested that Redx capitalise the whole of the loan, including all unpaid interest, into new shares.

The capitalisation price pursuant to the terms of the loan notes is 5.25p per share, which will result in the issue of 52.0 million new shares to Moulton.

In the red early Tuesday was KCR Residential REIT, down 9.3%, after saying that it has been unable to publish its results for the year to the end of June until the end of 2019. The company explained that it is in the process of finalising the audit and the results will be announced "as soon as possible".

The delay is procedural having been caused by time-delays during the course of the audit which started later than expected following the closing of the corporate transaction with Torchlight Fund, the company said.

KCR Residential REIT shares will be suspended on Thursday.

Gold was quoted at USD1,524.30 early Tuesday, up from USD1,515.03 at the London equities close on Monday.

Brent oil was trading at USD66.48 early Tuesday, firm on USD66.14 at the London equities close on Monday.

The economic events calendar on Tuesday has only US data. The Johnson Redbook retail sales index is at 1355 GMT, with the monthly house price index at 1400 GMT and the US consumer confidence index at 1500 GMT.

By Evelina Grecenko; evelinagrecenko@alliancenews.com

Copyright 2019 Alliance News Limited. All Rights Reserved.

More News
17 May 2023 14:44

Redx Pharma half-year loss doubles amid costs of failed Jounce merger

(Alliance News) - Redx Pharma PLC on Wednesday said its half-year loss nearly doubled, due to lower revenue and higher expenses, but it noted progress in therapeutics trials and said it "retains the foundations for longer term success".

Read more
11 May 2023 18:17

IN BRIEF: Redx reports positive preclinical data for fibrosis drug

Redx Pharma PLC - Macclesfield, England-based clinical-stage biotechnology company - Announces preclinical data for its lead fibrosis asset, RXC007, and the Discodin Domain Receptor 1/2 discovery programme, as presented yesterday at the Resistant Tumour Microenvironment, Keystone Symposia, in Vancouver. Notes the data presented were from preclinical models of pancreatic ductal adenocarcinoma and triple negative breast cancer in combination with chemotherapy and immunotherapy, as current standard of care. Says RXC007, in combination with gemcitabine/Abraxane in metastatic and high-extra cellular matrix patient-derived PDAC models, was shown to increase survival compared to single agent standard of care alone. The combination of RXC007 with standard of care provided a significant increase in median survival days from date of treatment in a dose dependent manner. These new data on RXC007 complement those also presented at the meeting by collaboration partner the Garvan Institute of Medical Research on REDX10616, a close analogue of RXC007. Taken together, these data provide a strong rationale for the potential of ROCK2 inhibition in combination with standard of care as a potential treatment for cancer-associated fibrosis. Redx plans to further investigate this treatment setting with the company's next-generation ROCK2 inhibitor, RXC007. Further, at the Keystone Symposia, data were also presented from Redx's DDR1/2 programme in combination with anti-PD-1 in TNBC models. Using a tool DDR1/2 inhibitor, in combination with anti-PD-1, in the TNBC E0771 model resulted in a statistically significant increase in survival when compared to the control group, an effect not observed with either single agent alone.

Read more
10 May 2023 15:45

UK earnings, trading statements calendar - next 7 days

Thursday 11 May 
3i Group PLCFull Year Results
Airtel Africa PLCFull Year Results
Eurocell PLCTrading Statement
Donegal Investment Group PLCHalf Year Results
Grainger PLCHalf Year Results
Hurricane Energy PLCFull Year Results
ICG Enterprise Trust PLCFull Year Results
IQE PLCFull Year Results
ITV PLCTrading Statement
John Wood Group PLCTrading Statement
Morgan Advanced Materials PLCTrading Statement
Rolls-Royce Holdings PLCTrading Statement
S4 Capital PLCQ1 Results
TBC Bank Group PLCQ1 Results
Friday 12 May 
Allianz Technology Trust PLCQ1 Results
Balfour Beatty PLCTrading Statement
Beazley PLCQ1 Results
CMO Group PLCFull Year Results
Monday 15 May 
CentralNic Group PLCFull Year Results
Cerillion PLCHalf Year Results
Currys PLCTrading Statement
Diploma PLCHalf Year Results
Equals Group PLCTrading Statement
Finsbury Growth & Income Trust PLCHalf Year Results
Instem PLCFull Year Results
JPMorgan Multi-Asset Growth & Income PLCFull Year Results
Westminster Group PLCFull Year Results
Tuesday 16 May 
Angling Direct PLCFull Year Results
boohoo Group PLCFull Year Results
Britvic PLCHalf Year Results
Burford Capital LtdFull Year Results
Cornerstone FS PLCFull Year Results
DCC PLCFull Year Results
Essentra PLCTrading Statement
Greggs PLCTrading Statement
Hyve Group PLCHalf Year Results
Imperial Brands PLCHalf Year Results
Land Securities Group PLCFull Year Results
Likewise Group PLCFull Year Results
Marston's PLCHalf Year Results
Renew Holdings PLCHalf Year Results
Smartspace Software PLCFull Year Results
Vodafone Group PLCFull Year Results
Zytronic PLCHalf Year Results
Wednesday 17 May 
Auction Technology Group PLCHalf Year Results
Bank of Georgia Group PLCQ1 Results
British Land Co PLCFull Year Results
Experian PLCFull Year Results
JD Sports Fashion PLCFull Year Results
Keller Group PLCTrading Statement
Ninety One PLC and LtdFull Year Results
Redx Pharma PLCHalf Year Results
Sage Group PLCHalf Year Results
Scottish Mortgage Investment Trust PLCFull Year Results
TP ICAP Group PLCQ1 Results
Watches of Switzerland Group PLCTrading Statement
  
Copyright 2023 Alliance News Ltd. All Rights Reserved.

Read more
3 Apr 2023 18:05

TRADING UPDATES: Redx confirms Jounce deal lapses, Tirupati seals deal

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

Read more
27 Mar 2023 14:34

Redx Pharma's bid to buy Jounce snubbed by Concentra's higher offer

(Alliance News) - Redx Pharma PLC on Monday noted that Jounce Therapeutics Inc, which it was close to buying, was bought by Concentra Biosciences LLC for a higher price.

Read more
27 Mar 2023 14:16

Jounce agrees Concentra Bioscences takeover, ditches Redx Pharma

(Sharecast News) - Jounce Therapeutics said on Monday that it was ditching a planned merger with AIM-listed Redx Pharma, opting instead to be bought by Concentra Bioscences.

Read more
8 Mar 2023 12:07

LONDON MARKET MIDDAY: Stocks down, pound below USD1.19 on US rate view

(Alliance News) - Stock prices in London were lower at midday on Wednesday, with investors still reeling from surprisingly hawkish comments by US Federal Reserve Chair Jerome Powell on Tuesday.

Read more
8 Mar 2023 11:52

Redx Pharma shares slide on RXC004 monotherapy blow

(Alliance News) - Redx Pharma PLC on Wednesday said first results of its phase 2 programme indicate were not sufficient enough to support the development of its RXC004 treatment as a monotherapy.

Read more
8 Mar 2023 10:42

AIM WINNERS & LOSERS: Redx drops on disappointing cancer drug results

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

Read more
7 Mar 2023 15:44

UK shareholder meetings calendar - next 7 days

Wednesday 8 March 
Amigo Holdings PLCGM re the company's capital position
boohoo Group PLCGM re adoption of the Growth Plan
Creo Medical Group PLCGM re open offer shares
Globalworth Real Estate Investments LtdEGM re grant options and script dividends
Henderson Opportunities Trust PLCAGM
Jersey Electricity PLCAGM
Thursday 9 March 
CT Capital & Income Investment Trust PLCAGM
Shoe Zone PLCAGM
WAG Payment Solutions PLCGM re proposed acquisition of Inelo
Friday 10 March 
Atrato Onsite Energy PLCAGM
Malin Corp PLCAGM
Mineral & Financial Investments LtdAGM
Monday 13 March 
BlackRock Energy & Resources Income Trust PLCAGM
Hercules Site Services PLCAGM
Hummingbird Resources PLCGM re strategic investment and placement
Ironveld PLCGM re second placing shares on AIM
Tuesday 14 March 
Georgia Capital PLCGM re company's transfer from Premium to Standard listing
MTI Wireless Edge LtdAGM
Redx Pharma PLCAGM
  
Copyright 2023 Alliance News Ltd. All Rights Reserved.

Read more
23 Feb 2023 10:24

Redx Pharma and Jounce Therapeutics agree transatlantic merger

(Alliance News) - Redx Pharma PLC and Jounce Therapeutics Inc on Thursday said they have agreed to an all-share merger that will create a USD425 million company focused on the treatment of cancer and fibrotic diseases.

Read more
23 Feb 2023 07:56

LONDON BRIEFING: WPP profit jumps in 2022; guides for further growth

(Alliance News) - Stocks in London were called to open slightly higher on Thursday, as investors were unfazed by a fairly uneventful set of policy meeting minutes from the US central bank.

Read more
9 Feb 2023 12:25

IN BRIEF: Redx Pharma makes progress on fibrosis candidate study

Redx Pharma PLC - Alderley Edge, England-based clinical-stage biotechnology company focused on the treatment of cancer and fibrotic disease - Updates on its lead fibrosis candidate, RXC007, which is currently being assessed in a phase 2a study. Says regulatory and ethics approvals for the 28-day and 12-week cohorts of the study have been received in five countries. Adds recruitment is progressing at a number of study sites, but says enrolment in the US 12-week cohort has not begun due to a partial US Food & Drug Adminstration hold, pending a data readout from an ongoing non-clinical programme. The requested data is expected later this year. US enrolment in the 28-day cohort is unaffected.

Read more
20 Dec 2022 14:29

EARNINGS SUMMARY: Goodwin achieves rise in interim profit and revenue

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Read more
16 Dec 2022 21:22

TRADING UPDATES: Uniphar takeover fails; Pearson notes redemption end

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Friday and not separately reported by Alliance News:

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.